testicular disease: A non-neoplastic or neoplastic disorder affecting the testis. Representative examples include torsion, infarction, germ cell tumor, sex cord-stromal tumor, lymphoma, and leukemia.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly males |
226837 |
2. Check conditionsNone |
226837 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
151 |
4. Check minimum number of eventsNone |
151 |
5. Include endpointsNone |
151 |
6. Filter based on genotype QC (FinnGen only) |
151 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Testicular dysfunction, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Testicular dysfunction
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1111 | - | 1111 |
| Only index persons | 1058 | - | 1058 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | - | 0.03 |
| Only index persons | 0.04 | - | 0.04 |
| Median age at first event (years) | |||
| Whole population | - | - | 39.11 |
| Only index persons | - | - | 39.11 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 151 | - | 151 |
| Unadjusted period prevalence (%) | 0.07 | - | 0.07 |
| Median age at first event (years) | 50.45 | - | 50.45 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 131
- Matched controls
- 1309
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E29.9
ICD-10 Finland
Testicular dysfunction, unspecified
1144.5
98.2
84
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
38.2
56.8
75
44
E29.8
ICD-10 Finland
Other testicular dysfunction
+∞
51.5
46
*
E29.1
ICD-10 Finland
Testicular hypofunction
58.1
21.0
24
5
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
123.9
20.2
21
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
11.6
11
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
59.5
9.8
11
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
12.0
9.6
17
16
Y28
ICPC
Limited function/disability (Y)
35.8
8.2
10
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.9
7.0
29
88
N02AX02
ATC
tramadol; systemic, rectal
2.7
6.9
65
348
A50
ICPC
General and Unspecified, Medication/prescr/renewal
13.2
6.7
11
9
N03AX16
ATC
pregabalin; oral
3.3
6.6
36
135
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
47
49
13.47
42.69
2.3
1.5
6.1
4.2
u/l
1.27
40
40
21
30
7.97
14.38
2.5
1.3
36.6
53.6
pmol/l
—
5
8
114
698
3.58
10.91
4.3
4.1
1.4
1.7
ug/l
1.36
108
638
133
963
4.20
8.49
4.1
3.6
1.8
2.0
mu/l
0.95
123
885
93
560
2.72
8.15
4.1
3.8
28.3
20.7
%
2.05
32
228
110
745
2.75
7.24
3.6
2.9
14.9
14.8
pmol/l
0.17
104
674
72
406
2.48
6.91
2.8
2.7
0.7
0.7
ug/l
0.03
36
233
23
74
3.49
6.20
7.6
2.3
63.1
66.0
ml/min/173m2
—
9
34
28
105
3.05
5.90
8.4
8.7
—
—
—
0
0
64
405
2.01
4.12
2.7
3.1
—
—
—
0
0
75
509
1.94
3.89
3.5
4.2
0.0
0.0
estimate
0.00
16
91
60
378
1.97
3.86
3.1
2.8
—
—
—
0
0
36
190
2.17
3.71
2.3
2.1
3.1
3.3
mg/l
0.23
31
167
30
147
2.30
3.68
2.4
1.7
—
—
—
0
0
75
516
1.90
3.67
2.7
3.1
0.0
0.0
estimate
0.00
14
84
74
509
1.89
3.61
2.8
3.0
0.0
0.0
estimate
0.00
15
90
110
868
1.98
3.45
7.4
8.1
77.9
77.1
u/l
0.05
104
832
63
418
1.87
3.39
5.3
3.3
24.4
33.8
ng/l
0.50
44
273
49
305
1.90
3.17
2.7
2.5
399.1
8907.5
umol/l
1.55
43
269
137
1194
2.59
3.04
16.3
12.7
26.8
23.3
mg/l
0.51
109
936
63
437
1.76
2.82
3.6
4.3
—
—
—
0
0
38
227
1.90
2.75
1.8
1.7
0.8
1.7
mg/l
1.34
30
175
43
268
1.85
2.73
3.3
3.2
0.0
0.0
estimate
0.49
16
86
26
136
2.10
2.71
2.7
2.0
—
—
—
0
0
129
1113
2.09
2.66
13.8
11.3
84.6
89.0
ml/min/173m2
1.31
111
928
84
642
1.70
2.58
7.2
10.3
4.1
4.2
e9/l
0.14
76
572
7
16
4.53
2.50
1.1
1.1
—
—
—
0
0
65
468
1.68
2.47
5.8
8.6
1.2
1.2
mmol/l
0.38
57
400
27
152
1.95
2.31
2.8
2.1
—
—
—
0
0
50
341
1.70
2.30
2.0
1.8
94.9
94.5
pmol/l
0.02
31
193
35
216
1.81
2.27
1.5
1.5
—
—
—
0
0
37
241
1.71
1.99
1.3
1.3
0.7
0.8
u/ml
0.50
12
74
32
202
1.74
1.92
3.6
3.7
6624.8
285.3
ng/l
0.47
23
159
42
286
1.65
1.91
3.9
2.5
0.5
0.5
e6/l
0.01
31
212
35
228
1.70
1.88
1.9
2.5
—
—
—
0
0
58
431
1.56
1.84
4.7
7.5
1.2
1.2
mmol/l
0.01
51
396
94
778
1.55
1.82
3.8
3.6
8.8
9.2
mm/h
0.09
86
734
127
1133
1.76
1.77
4.3
4.2
6.1
6.0
mmol/l
0.29
115
1059
20
116
1.83
1.58
3.0
4.8
211.4
247.1
u/l
1.03
20
111
136
1248
1.90
1.57
5.5
4.5
2.7
2.8
mmol/l
0.65
130
1177
25
156
1.72
1.56
1.2
1.2
10.1
20.5
iu/ml
—
9
46
41
295
1.54
1.46
3.9
3.3
2.3
2.3
mmol/l
0.08
35
264
101
871
1.48
1.45
3.1
3.1
—
—
—
0
0
6
22
2.80
1.45
1.3
1.4
—
—
—
0
0
134
1233
1.77
1.41
5.1
4.1
1.2
1.3
mmol/l
1.11
127
1163
30
203
1.60
1.39
1.6
1.7
434.4
424.1
pmol/l
0.07
25
176
39
283
1.51
1.33
3.2
3.2
1138.4
783.5
ng/l
0.40
33
230
21
131
1.70
1.32
1.8
1.9
—
—
—
0
0
20
123
1.72
1.32
4.0
4.1
27.3
28.8
%
0.22
12
91
25
165
1.62
1.28
2.5
2.5
0.4
0.3
e6/l
0.01
12
88
12
64
1.95
1.22
2.7
1.2
—
—
—
0
0
133
1233
1.66
1.20
5.1
4.2
4.5
4.6
mmol/l
0.91
126
1171
20
127
1.66
1.19
1.7
1.8
—
—
—
0
0
5
21
2.43
1.10
1.2
1.3
—
—
—
0
0
5
22
2.31
1.04
1.6
1.7
—
—
—
0
0
55
445
1.37
1.03
5.0
5.6
36.9
37.0
g/l
0.07
50
425
129
1198
1.53
1.03
12.9
12.9
44.2
42.4
%
2.73
104
974
22
150
1.55
1.00
2.3
2.4
15.7
14.9
umol/l
0.18
22
139
8
42
1.95
0.90
2.0
2.9
—
—
—
0
0
106
967
1.32
0.81
3.7
3.5
56.1
53.4
u/l
0.13
99
923
6
33
1.85
0.80
1.3
1.7
—
—
—
0
0
128
1203
1.42
0.78
4.9
3.8
1.4
1.4
mmol/l
0.12
121
1141
7
38
1.88
0.74
2.0
2.8
—
—
—
0
0
19
135
1.47
0.73
1.2
1.2
1.1
6.9
u/ml
1.12
12
58
5
25
2.03
0.73
1.0
1.1
—
—
—
0
0
5
26
1.95
0.71
1.0
2.7
—
—
—
0
0
24
182
1.38
0.66
2.8
2.3
0.3
1.0
e6/l
—
10
106
23
298
0.73
0.66
1.5
1.7
1.6
1.5
mmol/l
0.21
18
253
5
29
1.75
0.64
1.6
1.1
—
—
—
0
0
5
30
1.69
0.62
1.6
1.1
—
—
—
0
0
0
23
0.00
0.59
0.0
1.1
—
—
—
0
0
23
178
1.34
0.57
1.9
2.0
—
—
—
0
0
11
75
1.50
0.52
2.7
1.5
—
—
—
0
0
8
56
1.45
0.43
1.5
1.3
—
—
—
0
0
5
32
1.58
0.42
1.4
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
10.8
—
52.9
—
0
8
9
69
1.32
0.38
2.6
3.5
344.7
190.5
ng/l
—
9
62
7
52
1.36
0.31
1.1
1.0
—
—
—
0
0
18
151
1.22
0.26
2.1
1.7
1066.4
1224.2
nmol/l
0.26
11
122
9
75
1.21
0.25
15.3
14.6
26.4
24.1
mmol/l
—
9
67
9
76
1.20
0.25
1.7
1.7
—
—
—
0
0
13
106
1.25
0.24
8.0
15.9
133.3
126.7
g/l
0.64
13
100
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
5
48
1.04
0.09
3.0
2.9
—
—
—
0
0
6
56
1.07
0.09
1.2
1.3
—
—
—
0
0
11
111
0.99
0.00
4.0
2.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
2.7
—
1000.7
—
0
9
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
3.1
—
121.6
—
0
7
0
6
0.00
0.00
0.0
1.0
—
1111.7
—
0
6
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
6
59
1.02
0.00
2.2
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
3.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
0.00
0.0
1.4
—
137.2
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.9
—
14.1
—
0
8
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_TESTICDYSNAS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_TESTICDYSNAS | 1.564 [1.05, 2.32] | 0.026 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 694 males with E4_TESTICDYSNAS died.
Mortality risk
Mortality risk for people of age
years, who have E4_TESTICDYSNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.294% |
| 5 | No data | 1.847% |
| 10 | No data | 4.324% |
| 15 | No data | 8.11% |
| 20 | No data | 13.644% |
Relationships between endpoints
↥Index endpoint: E4_TESTICDYSNAS – Testicular dysfunction, other/unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data